GLP-3 RTA [Triple G] – 60mg

GLP-3 RTA (Triple G) is a triple incretin receptor agonist research peptide simultaneously targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors within a single compound representing the next generation of incretin based research beyond dual GIP/GLP-1 agonism. Hudson Science’s formulation supplies 60mg as a lyophilized vial, the highest concentration incretin agonist presentation in CSD’s range, designed for extended research protocols and higher dose response evaluations requiring significant compound availability from a single vial supply.

The addition of glucagon receptor agonism to the dual GIP/GLP-1 mechanism is the defining characteristic that distinguishes triple incretin agonists from their dual agonist counterparts. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression at the pancreas, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity and adipose tissue metabolic effects. Glucagon receptor agonism adds a third distinct pathway — directly stimulating hepatic glucose output regulation, energy expenditure through thermogenic activity, and lipolysis in adipose tissue. The simultaneous activation of all three receptors produces a synergistic metabolic response that has generated significant research interest in studies examining the additive and complementary effects of combined incretin and glucagon pathway co activation.

CSD’s triple incretin agonist range positions GLP-3 RTA as the most advanced formulation in the incretin research family, sitting above the dual agonist GLP-2 TRZ 20mg and GLP-2 TZ 15mg listings in terms of receptor pathway complexity. Researchers progressing from dual to triple incretin agonist research, or conducting comparative studies examining the incremental contribution of glucagon receptor co activation to the dual GIP/GLP-1 baseline, can source the complete incretin agonist compound family from a single verified Canadian supplier across three concentration and receptor profile options.

Every batch of Hudson Science’s GLP-3 RTA is third party lab tested for concentration accuracy and purity prior to release, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our incretin agonist range represents one of the most comprehensive peptide research sourcing options available from a Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside dual incretin agonist compounds in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.